Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

This study is testing a new drug called vosilasarm (EP0062) — alone and in combination with other treatments — for women with advanced or metastatic breast cancer that is hormone receptor-positive (ER+), HER2-negative, and also expresses a protein called androgen receptor (AR+). The goal is to find a safe dose and early signs of effectiveness. **You may be eligible if...** - You are a woman 18 or older - You have been diagnosed with metastatic or locally advanced breast cancer that is ER+, AR+, and HER2-negative - Standard treatments are no longer available, appropriate, or you have declined them - You can provide a tumor tissue sample (from surgery or biopsy) **You may NOT be eligible if...** - You have active brain metastases - Your overall health or organ function does not meet study requirements - You have had certain prior treatments that exclude you from the study Talk to your doctor to see if this trial is right for you.